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Essential hypertension is a complex disorder, caused by the interplay between many genetic variants, gene-gene interactions, and
environmental factors. Given that the renin-angiotensin system (RAS) plays an important role in blood pressure (BP) control,
cardiovascular regulation, and cardiovascular remodeling, special attention has been devoted to the investigation of single-
nucleotide polymorphisms (SNP) harbored in RAS genes that may be associated with hypertension and cardiovascular disease.
MicroRNAs (miRNAs) are a family of small, ∼21-nucleotide long, and nonprotein-coding RNAs that recognize target mRNAs
through partial complementary elements in the 3 -untranslated region (3 -UTR) of mRNAs and inhibit gene expression by
targeting mRNAs for translational repression or destabilization. Since miRNA SNPs (miRSNPs) can create, destroy, or modify
miRNA binding sites, this review focuses on the hypothesis that transcribed target SNPs harbored in RAS mRNAs, that alter
miRNA gene regulation and consequently protein expression, may contribute to cardiovascular disease susceptibility.
1.Introduction
Identifying the genes and mutations that contribute to
disease is a central aim in human genetics. Single nucleotide
polymorphisms (SNPs) are mutations that occur at genome
positions at which there are two distinct nucleotide residues
(alleles) that each appear in a signiﬁcant portion (i.e., a
minor allele frequency greater than 1%) of the human
population [1]. There are some estimated 14 million SNPs
[2] in the human genome that occur at a frequency of
approximately one in 1,200–1,500bp [3]. SNPs can aﬀect
protein function by changing the amino acid sequences
(nonsynonymous SNP) or by perturbing their regulation
(e.g., aﬀecting promoter activity [4], splicing process [5],
and DNA and pre-mRNA conformation). When SNPs occur
in 3 -UTRs, they may interfere with mRNA stability and
translation by altering polyadenylation and protein/mRNA
regulatory interactions. Recently, a new layer of posttran-
scriptional miRNA-mediated gene regulation has been dis-
covered and shown to control the expression levels of a large
proportion of genes (reviewed in [6]). Importantly, SNPs in
microRNA (miRNA) target sites (miRSNPs) represent a spe-
ciﬁc class of regulatory polymorphisms in the 3 -UTR that
may lead to the dysregulation of posttranscriptional gene
expression. Thus, for miRNAs acting by this mechanism, the
miRSNPsmayleadtoheritablevariationsingeneexpression.
Given that the renin angiotensin system (RAS) is intricately
involvedinthepathogenesisofcardiovasculardisease[7–12],
we review and discuss the presently available evidence for
miRSNPs-mediated RAS gene regulation and its importance
for phenotypic variation and disease.
2. CurrentView of
the Renin AngiotensinSystem
The RAS plays a critical role in regulating the physiological
processes of the cardiovascular system [reviewed in [7–14]].
The primary eﬀector molecule of this system, angiotensin
II (Ang II), has emerged as a critical hormone that aﬀects
the function of virtually all organs, including heart, kidney,
vasculature, and brain, and it has both beneﬁcial and2 International Journal of Hypertension
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Figure 1: Summary of the RAS incorporating the Ang peptide family and physiological eﬀects mediated via ATR subtypes. Under the
classical RAS schema, Ang II is produced, via renin and ACE, to act with equal aﬃnity on two ATR subtypes, AT1Ra n dA T 2R( l a r g ea r r o w s ) .
However, it is now appreciated that a number of breakdown products of Ang II, namely, Ang (1–7), Ang III, and Ang IV exert their own
unique eﬀects that are distinct (and often opposite) to those of Ang II. Such eﬀects are often mediated via newly recognized receptors such
as MasR for Ang (1–7) and AT4R (also known as IRAP) for Ang IV, or additionally via AT2R stimulation. ACE2 is also a new pathway for
the formation of Ang (1–7). Newly identiﬁed Ang receptor binding proteins associated with diﬀe r e n tA T Rs u b t y p e sm a ya l s om o d i f yA T R
activation. Thus, overstimulation of AT1R (and PRR) by Ang II, which can contribute to a plethora of cardiovascular disease processes, may
be counter-regulated by a number of non-AT1R mechanisms. Most notably, AT2R stimulation usually causes opposing eﬀects to AT1R, as
indicated. It is also likely that the MasR exerts a similar counter-regulatory role whereas the evidence is more preliminary and speculative
for AT4R/IRAP. In terms of mediators, Ang II itself stimulates AT2R whereas the shorter Ang peptides stimulate their cognate receptors and
possibly also AT2R.
pathological eﬀects [7–14]. Acute stimulation with Ang II
regulates salt/water homeostasis and vasoconstriction, mod-
ulating blood pressure, while chronic stimulation promotes
hyperplasia and hypertrophy of vascular smooth muscle
cells (VSMCs). In addition, long-term exposure to Ang II
also plays a pathophysiological role in cardiac hypertro-
phy and remodeling, myocardial infarction, hypertension,
atherosclerosis, in-stent restenosis, reduced ﬁbrinolysis, and
renal ﬁbrosis [7–14].
Ang II, an octapeptide hormone, is produced sys-
temically via the classical RAS and locally via the tissue
RAS [7–14]. In the classical RAS, circulating renal-derived
renin cleaves hepatic-derived angiotensinogen to form the
decapeptide angiotensin I (Ang I), which is converted by
angiotensin-converting enzyme (ACE) in the lungs to the
biologically active Ang II (Figure 1). Alternatively, a recently
identiﬁed carboxypeptidase, ACE2, cleaves one amino acid
f r o me i t h e rA n gIo rA n gI I[ 15–18], decreasing Ang II levels
andincreasingthemetaboliteAng1–7,whichhasvasodilator
properties. Thus, the balance between ACE and ACE2 is
an important factor controlling Ang II levels [15–18]. Ang
II is also further degraded by aminopeptidases to Ang III
(Ang 2–8) and Ang IV (Ang 3–8) (Figure 1)[ 7]. Although
the RAS was originally regarded as a circulating system,
many of its components are localized in tissues, including
the heart, brain, blood vessels, adrenal, kidney, liver and
reproductive organs, indicating the existence of local tissue
RASs [19]. In addition to ACE-dependent pathways of Ang
II formation, non-ACE pathways have also been described.
Chymotrypsin-like serine protease (chymase) may represent
an important mechanism for conversion of Ang I to Ang
II in the human heart, kidney, and vasculature and may
be particularly important in pathological conditions such as
coronary heart disease [20].International Journal of Hypertension 3
The biological responses to Ang II are mediated by
its interaction with two distinct high-aﬃnity G protein-
coupled receptors (GPCRs) designated AT1Ra n dA T 2R
(Figure 1)[ 7]. Both AT1Ra n dA T 2R possess similar aﬃnity
for Ang II [21]; however, pharmacologically, these receptors
can be distinguished according to inhibition by speciﬁc
antagonists. For example, AT1R are selectively antagonized
by biphenylimidazoles such as losartan (angiotensin receptor
blockers, ARB) [21] whereas tetrahydroimidazopyridines
such as PD123319 speciﬁcally inhibit AT2R[ 21, 22]. Inter-
estingly, all of the classical actions of Ang II, including
vasoconstriction,eﬀectsonﬂuidandelectrolytehomeostasis,
and inﬂuences on cellular growth and diﬀerentiation, have
been shown to be due to stimulation of AT1R located on the
plasma membrane of cells [7–12]. Additionally, the majority
of the pathophysiological eﬀects (i.e., cardiac hypertrophy
and remodeling, myocardial infarction, hypertension, etc.)
of Ang II are also mediated via the AT1R[ 7–12]. In contrast,
it is thought that the AT2R counter-regulates AT1Rf u n c t i o n
(reviewed in [13, 14]). It is also speculated that during
cardiovascular disease, AT2R upregulation and activation by
Ang II, or angiotensin peptide fragments (i.e., Ang III, Ang
IV, and/or Ang 1–7) may limit AT1R-mediated overactivity
and cardiovascular pathologies [13, 14].
Although the AT1Ra n dA T 2R have been intensively
investigated it is now clear that angiotensin fragments can
bind to and activate other receptor subtypes. For example,
Ang 1–7 acts on the Mas GPCR (MasR) and has vasodilatory
and antiproliferative eﬀects. This arm of the RAS is also
thought to counterbalance the eﬀects of Ang II acting on
the AT1R( Figure 1)( r e v i e w e di n[ 18]). Additionally, Ang
IV can bind to the angiotensin II type 4 receptor (AT4R)
or the membrane-bound, insulin-regulated aminopeptidase
(IRAP)(Figure 1) and mediate the enhancementof cognitive
function, modulate blood ﬂow, increase natriuresis, inhibit
cardiomyocyte hypertrophy, and improve endothelial func-
tion in animal models of atherosclerosis [23, 24].
Finally,recentstudiesnowsuggestthatrenin,theaspartyl
protease that cleaves angiotensinogen into Ang I, and
prorenin, its proenzyme inactive form, can bind to what is
now designated as the (pro)renin receptor (PRR) (reviewed
in [25–27]). Interestingly, the binding of renin/prorenin to
PRR has been shown to have two major consequences. First,
thebindingofrenintoitsreceptorincreasesangiotensinogen
conversion to Ang I by ﬁve-fold, and prorenin, which is
virtually inactive in solution, also displays enzymatic activity
following receptor binding [25–27]. Second, receptor-bound
renin/prorenin activates the MAP kinases ERK1/2 and
p38 pathways, which in turn, leads to the upregulation
of proﬁbrotic and cyclooxygenase-2 genes independent of
Ang II generation [25–27]. Therefore, the activation and
potentiation of renin/prorenin enzymatic activity, together
with speciﬁc PRR-mediated signaling, could have striking
eﬀects on cardiovascular regulation. Taken together, these
studies suggest that RAS is unexpectedly complex and
multilayered. New components and functions of the RAS
are still being unraveled and the physiological signiﬁcance,
and ultimately the clinical relevance, of these factors remain
largely undeﬁned.
3. Overview of miRNA Biology
MicroRNAs (miRNAs) are endogenous, short (20–23
nucleotide), and single-stranded nonprotein-coding RNA
molecules that regulate gene expression (reviewed in [28]).
These molecules act by binding to their target mRNAs,
preferentially to the 3 -UTR, using a partial base-pairing
mechanism. In order for a miRNA to give rise to functional
consequences, the 7-8 nucleotides (nt) at the most 5  end
must have exact complementarity to the target mRNA,
generally referred to as the “seed” region [29]. The current
model for inhibition of expression by a miRNA suggests
that a miRNA either inhibits translation or induces degra-
dation of its target mRNA, depending upon the overall
degree of complementarity of the binding site, number of
binding sites, and the accessibility of those binding sites
[30–32].
In mammals, computational predictions indicate that
miRNAs may regulate 60% of all human protein coding
genes [33], and have been increasingly implicated in the
control of various biological processes, including cell dif-
ferentiation, cell proliferation, development and apoptosis,
and many pathological processes such as cancer, Alzheimer’s
disease, and cardiovascular disease [34–36]. There are esti-
mated to be >1,000 miRNAs encoded by the human genome
[37, 38], each of which can act on multiple target mRNAs.
Conversely, individual mRNAs are commonly targeted by
multiple miRNAs, which results in a combinatorial repres-
sion of gene expression more robust than the suppression
thatresultsfromasingle miRNA[39,40].AlthoughmiRNAs
are known to mediate posttranscriptional gene silencing in
the cytoplasm, recent evidence indicates that at least some
fraction of mammalian miRNAs may also activate or inhibit
gene expression at the transcriptional level [41, 42]. Taken
together, these miRNA phenomena allow for enormous
combinatorial complexity and regulatory potential.
4. miRNA Biogenesis
Mature miRNAs are processed from primary miRNA tran-
scripts (pri-miRNAs), which are either transcribed from
independent miRNA genes or are portions of introns of
protein-coding RNA polymerase II transcripts (Figure 2)
[43–45].miRNAstendtoclusterthroughoutthegenomeand
many of these clusters are likely transcribed as polycistrons
[46–48]. Although little is known regarding the regulation
of miRNA transcription, it is recognized that miRNA
expression is usually regulated by established transcriptional
mechanisms. Interestingly, however, it has been shown that
each miRNA located within the same genomic cluster may
be transcribed and regulated independently [49].
During the transcriptional process, pri-miRNAs fold
into hairpin structures containing imperfectly base-paired
stems and are endonucleolytically cleaved by the nuclear
microprocessor complex formed by the RNase III type
endonuclease Drosha and the DiGeorge critical region
8 (DGCR8) protein [50]. The Drosha/DGCR8 complex
processes pri-miRNAs into ∼70-nucleotide hairpins known
as pre-miRNAs (Figure 2)[ 28, 51]. In animals, pre-miRNAs4 International Journal of Hypertension
TRBP
Drosha
DGCR8
RNA Pol II/III
Dicer
AGO2
AAAAA
AAAAA
3´
3´
3´
3´
3´
3´
3´
3´
3´
5´
5´
5´
5´
5´
5´
5´
5´
5´
Cytoplasm Nucleus
MicroRNA gene or intron
Transcription
Pri-miRNA
Processing
Pre-miRNA
AGO1–4
AGO1–4
Exportin-5
Maturation
Strand selection and
RISC formation
mRNA target cleavage
Translational repression
and/or deadenylation
Decreased mRNA target
protein levels
Figure 2: Schematic representation outlining miRNA biogenesis including transcription, maturation, and miRNA/mRNA targeting. This
diagram also outlines two potential mechanisms for miRNA/mRNA silencing. The speciﬁc details discussing these processes are included in
the text.
areexportedfromthenucleustothecytoplasmviaExportin-
5, where they are cleaved by Dicer complexed with the
TAR RNA binding protein (TRBP), to yield ∼20-bp miRNA
duplexes. In principle, the miRNA duplex could give rise to
two diﬀerent mature miRNAs. However, in a manner similar
to siRNA duplexes, only one strand is usually incorporated
into miRNA-induced silencing complexes (miRISCs) and
guides the complex to target mRNAs; the other strand
is degraded (the complementary miRNA∗ strand) [52].
This functional asymmetry depends on the thermodynamic
stability of the base pairs at the two ends of the duplex, with
the miRNA strand, which has the least stable base pair at its
5  endintheduplex,beingloadedintothemiRISC[53].Still,
recent data suggest that both arms of the pre-miRNA hairpin
c a ng i v er i s et om a t u r em i R N A s[ 28, 45, 51].
5. miRNA/mRNA Silencing
Although the details are not well understood, pre-miRNA
processing by Dicer is coupled with the assembly of
miRNAs into ribonucleoprotein complexes called micro-
RNPs (miRNPs) or miRISCs [28, 51, 54]. One of the key
components of miRNPs is the Argonaute (AGO) protein
family, AGO1 to AGO4, and while all four AGO proteins
function in miRNA repression only AGO2 functions in
mRNA target cleavage (Figure 2)[ 54, 55]. Once the miRNA
is processed, the mature miRNA acts as an adaptor for
miRISC to speciﬁcally recognize and regulate particular
mRNAs.ItiscurrentlythoughtthatthemiRNA-loadedRISC
is targeted to a given mRNA by a mechanism where the
miRISC binds many sites nonspeciﬁcally until the correct
target site is found [56].
With few exceptions, miRNA binding sites in animal
mRNAs are present in the 3 -UTR and mature miRNAs
base pair with their target mRNAs imperfectly, following a
set of rules that have been identiﬁed by experimental and
bioinformatics analyses [29, 57–60]. First, miRNA/mRNA
target recognition involves Watson-Crick base pairing that
must be perfect and contiguous at the 5 -end of the miRNA
from nucleotides 2 to 8. This section represents the “seed”
regionandnucleatesthemiRNA-mRNAassociation.Second,
G:U wobble pairing in the seed sequence is highly detrimen-
tal to miRNA function despite its favorable contribution to
RNA:RNA duplexes. Third, an A residue across position 1
of the miRNA, and an A or U across position 9, improve
the site eﬃciency, although they do not need to base pair
with miRNA nucleotides. Fourth, it has been established that
miRNAs that have suboptimal 5  Watson-Crick base pairing
need substantial complementarity to the miRNA 3  half to
stabilize the interaction and to be functional. Finally, the
context of the miRNA’s binding sites harbored in the 3 -UTRInternational Journal of Hypertension 5
of target mRNAs, also inﬂuence the functional importance
of these sites [61]. For example, miRNA site eﬃcacy can be
improved if the site is positioned at least 15 nt downstream
from the stop codon, away from the center of long 3 -UTRs,
and near AU-rich nucleotide regions. These factors can make
the3 -UTRregionslessstructuredandhencemoreaccessible
to miRNP recognition.
WhenanendogenousmiRISCprogrammedwithmiRNA
binds to a recognition site that is perfectly complementary,
this target mRNA will be cleaved by the miRISC (Figure 2)
[56, 62–65]. In contrast, miRISCs that are imperfectly
matched with target mRNAs can repress translation initia-
tion at either the cap-recognition stage [66–70] or the 60S
subunit joining stage [71]. Alternatively, binding of miRISCs
can induce deadenylation and decay of target mRNAs [62].
6. Computational Algorithms to
PredictmiRNA/mRNA Targets
Computational miRNA/mRNA target programs remain the
only source for rapid prediction of miRNA recognition sites
harbored within the 3 -UTR of target mRNAs. Therefore,
the development of reliable computational target prediction
programs is critical in advancing our understanding of
miRNA function. Given that miRNA functionality usually
requires seed sequence complementarity [28, 61] the main
prediction feature used in most of these programs is the
sequencealignmentofthemiRNAseedtothe3 -UTRofcan-
didate target genes. Additionally, many current algorithms
also utilize conservation of miRNA/mRNA target sites across
species as an important parameter for the identiﬁcation of
bona ﬁde targets; notably however, the conservation of a
miRNA binding site harbored in a given mRNA target is not
a requirement for a functional miRNA.
A recent review article [72] comparing eight of the
most commonly used algorithms for miRNA target pre-
diction for the human and mouse genome programs
demonstrated that the four top algorithms, DIANA-
microT 3.0 (http://microrna.gr/microT)[ 73], TargetScan 5.0
(http://www.targetscan.org/) [74], Pictar (http://pictar.org/)
[75], and ElMMo (from http://www.mirz.unibas.ch)[ 76]a l l
have a precision of ∼50% with a sensitivity that ranges from
6% to 12%. Of the top four performing programs, it is
important to note that TargetScan is the most up-to-date
regarding the number of miRNAs and genes used and Pictar
is least updated [72]. Most investigators assume that mRNA
targets predicted by more than one algorithm are more
accurate than other targets thus leading to higher prediction
precision. However, Alexiou et al. [72] demonstrated that
many of the algorithm combinations performed worse than
the prediction of a single algorithm. These investigators
reason that the better speciﬁcity of a combination is achieved
by a higher price for the sensitivity. Taking this into
account, our laboratory has analyzed all of the classical and
nonclassical RAS components for putative miRNA binding
sites by the TargetScan algorithm (Table 1). Importantly, this
analysis suggests that miRNAs may play a major role in
regulating the expression of RAS proteins.
Although many programs are available online for the
prediction of individual mRNA targets of miRNAs (see
above),theidentiﬁcationofauthenticmRNAtargetsremains
problematic. Mammalian miRNAs bind to the mRNA with
imperfect complementarity thus how binding sites are
recognized is only partially understood. Therefore, some
bioinformatically predicted targets turn out to be false
and others are entirely overlooked. Experimental validation
of targets is therefore an important step in deﬁning the
functions of individual miRNAs (for review, see [77]).
7. ExperimentallyValidated
miRNA/RAS Targets
Although classical and nonclassical RAS components harbor
putative miRNA binding sites, very few of these sites
have been experimentally validated. Our laboratory has
demonstrated that miR-155 speciﬁcally interacted with
the algorithm-predicted binding site harbored in the 3 -
UTR of the human AT1R (hAT1R) mRNA (Table 1)[ 78,
79]. Additionally, miR-155 gain-of-function experiments
(i.e., cells were transfected with partially double-stranded
RNAs that mimic the Dicer cleavage product and are
subsequently processed into their respective mature miR-
NAs) inhibited the expression of the hAT1R and also
attenuated Ang II-induced signaling via the hAT1Ri n
ﬁbroblasts and vascular smooth muscle cells (VSMCs)
[78, 79]. These results also demonstrated that transfection
with miR-155 did not signiﬁcantly decrease hAT1Rs t e a d y
state mRNA levels, suggesting that miR-155 can decrease
hAT1R expression by inhibiting translation of the mRNA,
rather than targeting it for degradation. In contrast, loss-
of-function experiments (i.e., cells were transfected with
miRNA inhibitors; antisense single-stranded chemically-
enhanced oligonucleotides, ASO) demonstrated that trans-
fection of anti-miR-155 not only increased hAT1Re x p r e s -
sion but also enhanced Ang II-induced signaling via the
hAT1R, indicating that miR-155 plays a physiological role
in regulating the expression of hAT1Rs in human ﬁbroblasts
and VSMCs [78, 79]. Recently, our laboratory also demon-
strated that hAT1R expression can be regulated by miR-802
[80].
In support of the miR-155/hAT1R studies described
above, trisomy 21 (Ts21) mediated overexpression of miR-
155(thebic/miR-155geneislocatedonhumanchromosome
21 and is triplicated in Down syndrome [DS] individuals)
[81, 82] resulted in the attenuation of hAT1R protein levels
in ﬁbroblasts isolated from one monozygotic twin with DS
when compared to ﬁbroblasts isolated from the unaﬀected
euploid twin [83]. Interestingly, individuals with DS have
signiﬁcantly lower systolic and diastolic blood pressures
[84–87], a reduced risk of vascular anomalies [88], and
a low prevalence of coronary artery disease [89–93] when
compared with the general population. Given that the over-
expression of miR-155 in Ts21 results in attenuated hAT1R
protein levels, we speculate that this may be one mechanism
which contributes to the lack of cardiovascular disease
observed in individuals with DS [84–87].6 International Journal of Hypertension
Table 1: TargetScan∗ algorithm-predicted RAS putative miRNA/mRNA target sites.
RAS Component Total Conserved miRNA Targets Total Poorly Conserved miRNA Targets Overall Total miRNA Targets
AGTR1 (AT1R) 0 56 56
AGTR2 (AT2R) 2 96 98
ACE 0 26 26
ACE2 1 57 58
AGT 1 31 32
REN 0 15 15
ATP6AP2 (PRR) 4 49 53
MAS1 (MasR) 0 12 12
LNPEP (AT4R) 5 42 47
∗Source: TargetScan (April, 2009). The number of potential targets is dramatically dependent upon the algorithm utilized.
Finally, Boettger et al. [94] demonstrated by genomic,
proteomic, and transcriptional analyses that mouse ACE
mRNA is a miR-145 target. The miR-143/-145 gene cluster
includes miR-143 and miR-145, which lie within a 1.7-kb
highly conserved region of mouse chromosome 18 [94].
miRNA microarray hybridization experiments revealed that
miR-143 and miR-145 are enriched in murine vascular
smooth muscle cells (VSMCs) [94, 95]. In the mouse
embryo, miR-143/-145 expression is restricted to heart, vas-
cular, and visceral SMCs [94, 95]. During late fetal and post-
natal development, miR-143/-145 expression is downregu-
lated in the heart but persists in vascular and visceral SMCs.
Homozygous miR-143/-145 knockout mice were viable but
exhibited thinning of the arterial tunica media (muscular
layer), with a reduction in the number of contractile VSMCs
and a concomitant increase in the number of proliferative
VSMCs [94]. Physiological characterization of miR-143/-
145 deﬁcient mice and arterial segments from these animals
revealed defects in Ang II-induced VSMC contractility and
homeostatic control of blood pressure. Consistent with this
observation, pharmacological inhibition of ACE or the AT1R
partially reversed vascular dysfunction and normalized gene
expression in the mutant mice [94]. Since miR-145 regulates
the expression of ACE, when the miR-143/-145 gene cluster
is mutated, the levels of membrane-bound ACE in VSMCs
increase, causing the chronic stimulation of VSMCs by Ang
II, which in turn results in desensitization and “angiotensin
resistance” of VSMCs. Given that miR-143/145 mutant mice
developed neointimal lesions in the absence of hyperlidemia,
lipid depositions, and foam cells also highlights the potential
role of VSMCs in the pathogenetic process leading to
atherosclerosis. The enhancement of Ang II signaling due to
the increased expression of ACE would certainly contribute
to this process, since increased levels of Ang II have been
shown to promote atherosclerotic lesions in apoE-deﬁcient
mice [96].
Although the hAT1R and mouse ACE are experimentally
validated targets of miRNAs, it is important to note that
none of these recognition sites are conserved across species
(Table 1). Therefore, although miR-155 and -802 repress
hAT1R expression in humans, these miRNAs will not lead to
the repression of AT1R levels in mice or rats. Likewise, miR-
145 will repress ACE expression in mice but will not regulate
ACE levels in humans.
8. miRSNPs
Since a large number of miRNA binding sites are harbored
in the 3 -UTRs of RAS component mRNAs (Table 1), there
is a high probability that SNPs will occur within miRNA
target sites. By deﬁnition, miRSNPs have the potential to
create, destroy, or modify the eﬃciency of miRNA binding,
if the SNP occurs in the seed region (i.e., the region of
base-pairing between nucleotides 2 and 8 of the miRNA and
complementary nucleotides in the target mRNA) [97–99].
Based on this deﬁnition, there are two mechanisms by which
miRSNPs can be functionally important: as a gain- or as a
loss-of-function variation. A gain-of-function eﬀect would
result if the SNP enhances the targeting of the miRNA or
creates a new target site in the 3 -UTR of the mRNA. In
this scenario, protein expression of the target mRNA would
be attenuated. In contrast, a loss-of-function eﬀect would
result when the SNP decreases or abolishes the interaction
of the miRNA with its mRNA target, thus resulting in
an augmentation of protein expression. In support of this
conclusion, miRSNPs have been implicated in Tourette
syndrome [100], papillary thyroid cancer [101], muscularity
in sheep [102], hereditary spastic paraplegia type 31 [103],
methotrexate resistance [104], breast cancer [105], and
tumor susceptibility [106]. These examples include both
gain- and loss-of-function miRSNPs.
9.The HumanAT1R GeneandmiRSNPs
The hAT1R gene has been found to be highly polymorphic
[107]. In particular, a SNP has been described in which there
is an A/C transversion at position +1166 (i.e., 1166 base-
pairs downstream from the start codon, dsSNP# rs5186)
located in the 3 -UTR of the hAT1R gene. The increased
frequency of the +1166 C-allele has been associated with
hypertension [108–115], cardiac hypertrophy [116–118],
aortic stiﬀness [119–121], myocardial infarction [122], heart
failure [123–125], abdominal aortic aneurysms [126, 127],International Journal of Hypertension 7
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[79].
and increased oxidative stress levels in human heart failure
[128]. However, the physiological relevance of this poly-
morphism is uncertain because of its location within the
noncoding region of the hAT1R gene. Since our laboratory
has previously demonstrated that miR-155 interacted with a
speciﬁc cis-response element localized in the hAT1R3  -UTR
[78], we investigated whether or not there was a correlation
between the +1166 A/C SNP and the miR-155-binding site
[79, 83]. Importantly, computer alignment revealed that the
+1166 A/C SNP occurs within the cis-response element at
the site where miR-155 was shown to interact (Figure 3).
The interaction between miR-155 and the hAT1R3  -UTR
harboring the A-allele fulﬁlls the seed sequence rules [29]
since there is a 7-bp region of complementarity between
the 5  end of miR-155 and the hAT1Rm R N At a r g e ts i t e
(Figure 3(a)). In contrast, if a hAT1R mRNA that harbors
the +1166 C-allele is expressed, the complementary seed
site is interrupted (Figure 3(b)), and the thermodynamics
of the miRNA:mRNA duplex would be signiﬁcantly altered
(i.e., a decrease in free energy) [79]. Therefore, the presence
of the +1166 C-allele miRSNP would decrease the ability
of miR-155 to interact with the cis-regulatory site located
in the hAT1R3  -UTR. As a consequence, it would be
expected that aberrantly high levels of the hAT1Rw o u l db e
synthesized. In support of this hypothesis we demonstrated
that when the hAT1R cis-response element harboring the C-
allele was present in luciferase mRNAs, the ability of miR-
155 to inhibit luciferase activity was signiﬁcantly attenuated
[79]. When identical experiments were performed utilizing
mutant miR-155, which restored perfect Watson-Crick com-
plementarity, luciferase activity was decreased to levels that
were comparable with experiments utilizing the hAT1R cis-
response element harboring the A-allele and miR-155 [79].
To further demonstrate that the presence of the +1166 C-
allelecaninﬂuencehAT1Rdensity,expressionconstructsthat
produced hAT1R mRNAs containing either the A- or C-allele
were cotransfected with miR-155 or mut-miR-155. These
experiments again demonstrated that when seed sequence
complementarity was not fulﬁlled, regardless of whether
miR-155 or mutant miR-155 was utilized, hAT1Rl e v e l s
were always higher than the levels obtained when perfect
complementarity was present between the miRNA and the
hAT1R cis-response element [79]. Taken together, these
studies provide the ﬁrst feasible biochemical mechanism by
which the +1166 A/C polymorphism (i.e., miRSNP) can
leadtoincreasedhAT1Rdensitiesandpossiblycardiovascular
disease.
10. miRSNPS andRAS Component Genes
To begin to investigate whether other RAS components
harbored SNPs in their 3 -UTRs which created miRSNPs,
the SNP Geneview Report (http://www.ncbi.nlm.nih.gov/
nucleotide/) for each gene was surveyed and all of the iden-
tiﬁed SNPs were analyzed utilizing the Patrocles algorithm
(http://www.patrocles.org/)[ 99]. Speciﬁcally the “Patrocles
Finder” was utilized since it allows one to compare two
sequences and subsequently determines the miRNA binding
sites that are diﬀerent between the two sequences. Thus,
a region of the transcribed 3 -UTR which harbored the
common allele was compared with the same region contain-
ing the mutated allele (select motif length: human 7 mers)
and the generation of putative miRSNPs was determined
(Table 2). Importantly, this analysis demonstrated that the
3 -UTRs of the RAS components harbor a number of
miRSNPs some of which alter or destroy legitimate miRNA
binding sites and others that create novel, illegitimate
target sites. Hypothetically, if a loss-of-function miRSNP
occurred in the AGTR1, ACE, AGT, REN, or ATP6AP2 gene,
an increased incidence of hypertension, cardiac/vascular
remodeling,andatherosclerosiswouldbeobserved(Table 3).
In contrast, if a loss-of-function miRSNP occurred in
the AGTR2, ACE2, MAS1, or LNPEP gene, a decreased
incidence of hypertension, cardiac/vascular remodeling, and
atherosclerosis would be expected (Table 3).8 International Journal of Hypertension
Table 2: Patrocles∗ algorithm-predicted RAS component miRSNPs.
RAS Component dbSNP# Hetero dbSNP bp from Stop Codon Loss of Function miRSNP Gain of Function miRSNP
AGTR1 (AT1R)
rs5184 0.069 A>G 2 miR-668
rs56343250 N.D. 40 mR-1237, -1248
rs5185 0.130 T>G 70 miR-302c, -573 miR-143∗, -301a
rs12721277 0.028 G>A 82 miR-579
rs5186 0.500 A>C 86 miR-155
rs5187 N.D. A>G 93 miR-562, -548n miR-646
rs1799870 0.055 C>T 135
rs5188 0.109 G>A 317 miR-1197
rs55707609 N.D. A>T 335 miR-299-3p
rs5189 0.500 G>T 437 miR-570
rs12721276 0.061 C>A 461 miR-128, -27a
rs12721275 0.055 C>T 484 miR-143∗
rs12721274 0.028 T>C 556 miR-641
rs440881 N.D. A>C 565 miR-30b
rs1051649 N.D. C>T 680 miR-1197 miR-7
rs35533650 N.D. A>G 704
rs380400 0.500 A>G 798
rs35393661 N.D. ->AT 803
AGTR2 (AT2R)
rs34589510 N.D. ->T5 7
rs5193 0.241 G>T 199
rs5194 0.499 A>G 205 miR-1229
rs11091046 0.496 A>C 501
rs17231436 0.131 G>C 581 miR-384
rs41312570 N.D. C>T 645 miR-301a, -130a
rs17231443 0.025 C>G 816 miR-548f, -570
rs17237806 0.050 C>T 837
rs12858432 N.D. C>T 906
rs12845035 0.030 C>G 1103 miR-361-3p
rs17237820 0.073 A>T 1111 miR-548a-3p
rs17231478 0.038 G>T 1185
rs17237827 0.025 A>G 1274
rs17231450 0.050 C>A 1318 miR-150∗
rs17231457 0.050 A>C 1536 miR-571
ACE None
ACE2 None
AGT
rs61762526 0.007 G>T3 3
rs5042 0.008 C>T 40 miR-486-3p
rs4753 0.021 G>C 158 miR-337-5p
rs61751079 0.002 G>A 159 miR-639, -539
rs5043 0.021 T>C 167
rs61751080 0.002 T>A 168
rs11684 N.D. C>T 184 miR-103, -107
rs1803103 N.D. G>T 187 miR-483-3p
rs15022 N.D. G>T 188 miR-483-3p
rs1803104 N.D. A>G 316
rs1803106 N.D. A>C 338 miR-129-5p miR-335∗
rs61751081 0.002 C>T 350
rs5044 0.029 T>G 423 miR-1283, -606
rs61762525 0.004 C>T 473 miR-548l, -559
rs7079 0.312 C>A 556 miR-218-1∗, -584
rs55720804 0.035 C>- 573International Journal of Hypertension 9
Table 2: Continued.
RAS Component dbSNP# Hetero dbSNP bp from Stop Codon Loss of Function miRSNP Gain of Function miRSNP
rs61751082 0.023 C>- 575
REN rs11799601 0.500 C>A 48 miR-326, -330-5p
r11571124 0.041 C>T 145 miR-138 miR-150∗
ATP6AP2 (PRR) rs5963816 0.296 A>T 266 miR-664
rs6609080 0.186 A>G 358 miR-1179
rs9062 N.D. G>T 654 miR-508-5p miR-410
rs10536 0.334 A>G 761 miR-802 miR-140-3p, -497∗
rs1060063 0.340 T>C 809
MAS1 (MasR) None
LNPEP (AT4R)
rs17087239 0.004 C>T 61 miR-992, -15b
rs39602 0.488 C>G 217
rs75912980 0.180 T>A 364 miR-1225-5p, -9
rs1057808 0.014 T>C 408 miR-922, -15b
rs3756618 0.028 A>T 501 miR-22∗, -26b∗ miR-223
rs35838718 N.D. A>- 561
rs79818663 0.105 G>T 594
rs77639920 N.D. C>T 614 miR-664∗
rs62377081 N.D. G>T 695 miR-302a∗, -1264 miR-548l
∗Source: http://www.patrocles.org/.
Table 3: Physiological ramiﬁcations of RAS miRSNPs.
RAS Component Loss of Function
miRSNP Physiological Result
Gain of
Function
miRSNP
Physiological Result
AGTR1 (AT1R) AT1R↑
Hypertension
Cardiac/vascular
remodeling
Atherosclerosis
AT1R↓
Antihypertensive
Antiremodeling
Anti-atherosclerosis
ACE ACE↑ ACE↓
AGT AGT↑ AGT↓
REN REN↑ REN↓
ATP6AP2 (PRR) PRR↑ PRR↓
AGTR2 (AT2R) AT2R↑
Antihypertensive
Antiremodeling
Antiatherosclerosis
AT2R↓ Hypertension
Cardiac/vascular
remodeling
Atherosclerosis
ACE2 ACE2↑ ACE2↓
MAS1 (MasR) MasR↑ MasR↓
LNPEP (AT4R) AT4R↑ AT4R↓
11. Conclusion
miRNAs have been increasingly implicated in the control of
various biological processes, including cell diﬀerentiation,
cell proliferation, development and apoptosis, and many
pathological processes such as cancer, Alzheimer’s disease,
and cardiovascular disease [34–36]. Importantly, several
studies which have now demonstrated that polymorphisms
at the miRNA target site in the 3 -UTRs of transcribed
mRNAs can have detrimental eﬀects given that miRSNPs
can lead to the modulation of gene expression [79, 83, 100–
106]. In support of this hypothesis, a recent study suggested
that diﬀerences in SNP allele frequency among ethnic groups
account for diﬀerences in gene expression [129]. Therefore,
we speculate that miRSNPs can modulate RAS phenotypic
geneexpressiondiversities,atleastinpart,throughalteration
of miRNA target binding capability, ultimately leading to
diﬀerences in the susceptibility to complex genetic disorders,
such as cardiovascular disease.
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